Correction to “Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAcute Myeloid Leukemia Research · Chronic Myeloid Leukemia Treatments · Histone Deacetylase Inhibitors Research
Cai Y, Rui J, Ding Z, Xie J, Jin Z., Xiao J., Xu Y. Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy In Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia. Cancer Med. 2025 Jul;14(14): e71037.
In the published version of this article, the first authorship was listed solely as Yiming Cai. The first authorship attribution was incomplete. The authorship statement should be added: “Yiming Cai, Jingwen Rui, and Zhengwen Ding contributed equally to this work.”
We apologize for this error.